欧洲肾脏替代治疗患者超额死亡率趋势:2002-2015年ERA-EDTA登记数据
本研究基于ERA-EDTA登记系统与WHO数据库,采用相对生存模型分析2002-2015年280,075例欧洲成人肾脏替代治疗患者的超额死亡率趋势。结果显示患者超额死亡风险每五年下降16%(RER 0.84),主要归因于透析患者风险下降14%,而移植受者超额死亡风险反而增加16%。
要点
- 肾脏替代治疗患者超额死亡风险每五年下降16%(RER 0.84,95%CI 0.83-0.84)。
- 透析患者超额死亡风险每五年下降14%(RER 0.86,95%CI 0.85-0.86)。
- 肾移植受者超额死亡风险每五年增加16%(RER 1.16,95%CI 1.07-1.26),部分亚组恶化。
核心结论
- 肾脏替代治疗患者生存改善不仅源于一般人群生存率提高,也源于患者群体本身生存改善,且主要体现在透析患者。
研究设计与样本
- 基于ERA-EDTA登记系统与WHO数据库,纳入2002-2015年280,075例欧洲成人肾脏替代治疗患者,采用相对生存模型分析。
- 模型按年龄和肾脏替代治疗方式分层,并校正性别、原发肾病和国家。
主要发现
- 总体超额死亡风险每五年下降16%(RER 0.84;95%CI 0.83-0.84)。
- 透析患者超额死亡风险每五年下降14%(RER 0.86;95%CI 0.85-0.86)。
- 透析患者动脉粥样硬化性心血管病死亡超额风险每五年下降28%(RER 0.72;95%CI 0.70-0.74)。
- 透析患者非动脉粥样硬化性心血管病死亡超额风险每五年下降10%(RER 0.90;95%CI 0.88-0.92),感染死亡超额风险每五年下降10%(RER 0.90;95%CI 0.87-0.92)。
- 肾移植受者超额死亡风险每五年增加16%(RER 1.16;95%CI 1.07-1.26),多数死因超额风险稳定,但部分亚组恶化。
临床怎么用
- 透析患者超额死亡风险持续改善,提示透析管理质量提升有效,应继续强化心血管病和感染防治。
- 肾移植受者超额死亡风险增加,需关注移植后长期随访中部分亚组的死亡风险恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to investigate whether the improvement in survival seen in patients on kidney replacement therapy reflects the enhanced survival of the general population. Patient and general population statistics were obtained from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry and the World Health Organization databases, respectively. Relative survival models were composed to examine trends over time in all-cause and cause-specific excess mortality, stratified by age and modality of kidney replacement therapy, and adjusted for sex, primary kidney disease and country. In total, 280,075 adult patients started kidney replacement therapy between 2002 and 2015. The excess mortality risk in these patients decreased by 16% per five years (relative excess mortality risk (RER) 0.84; 95% confidence interval 0.83-0.84). This reflected a 14% risk reduction in dialysis patients (RER 0.86; 0.85-0.86), and a 16% increase in kidney transplant recipients (RER 1.16; 1.07-1.26). Patients on dialysis showed a decrease in excess mortality risk of 28% per five years for atheromatous cardiovascular disease as the cause of death (RER 0.72; 0.70-0.74), 10% for non-atheromatous cardiovascular disease (RER 0.90; 0.88-0.92) and 10% for infections (RER 0.90; 0.87-0.92). Kidney transplant recipients showed stable excess mortality risks for most causes of death, although it did worsen in some subgroups. Thus, the increase in survival in patients on kidney replacement therapy is not only due to enhanced survival in the general population, but also due to improved survival in the patient population, primarily in dialysis patients.
引用
- Boenink R, Stel VS, Waldum-Grevbo BE, et al. Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy. Kidney Int. 2020. PMID: 32569654. doi:10.1016/j.kint.2020.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。